Enters the bloodstream directly, often with higher absorption
The compound doesn't build dependency, but its protective effects disappear fast
Patients who benefit most from dual-compound therapy share specific clinical characteristics: inadequate blood sugar control on monotherapy, concurrent cardiovascular disease or high heart disease risk, chronic kidney disease in early stages, and significant weight-loss resistance despite lifestyle changes
95% CI, 0.300.43)
This study aims to investigate the causal relationships between GLP1RA and 10 common mental illnesses: AUD, CUD, SZ, attention deficit and hyperactivity disorder (ADHD), anorexia nervosa (AN), anxiety disorder (ANX), autism spectrum disorder (ASD), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD)